TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15366275
Drug: Evidence based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evidence based medicine adopting realism
Study: 11820707
Drug: Risedronate 5
Normalized name: risedronate 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate 5 mg daily for 3 months
Study: 22094303
Drug: Individualised patient
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualised patient care as an adjunct to standard care
Study: 17591563
Drug: CHOP chemotherapy
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CHOP chemotherapy (Cyclophosphamide, doxorubicin, vincristine, and prednisone)
Study: 17591563
Drug: CHOP chemotherapy
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CHOP chemotherapy with rituximab
Study: 17591563
Drug: Dose-dense and/or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-dense and/or dose-intense regimens
Study: 2396473
Drug: Parotin (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parotin (oral adjuvant)
Study: 2396473
Drug: Taurine (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taurine (oral adjuvant)
Study: 2396473
Drug: Taurine +
Normalized name: Taurine
DrugBank: Taurine (DB01956)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Taurine + Lithium (oral adjuvant)
Study: 2396473
Drug: Taurine +
Normalized name: Taurine
DrugBank: Taurine (DB01956)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Taurine + Parotin (oral adjuvant)
Study: 2396473
Drug: Taurine +
Normalized name: Taurine
DrugBank: Taurine (DB01956)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Taurine + Parotin + Lithium (oral adjuvant)
Study: 2396473
Drug: Taurine +
Normalized name: Taurine
DrugBank: Taurine (DB01956)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Taurine + Lithium + Parotin (oral adjuvants)
Study: 2396473
Drug: Non-adjuvanted vaccines
Normalized name: respiratory syncytial virus pre-fusion F protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-adjuvanted vaccines (control)
Study: 314716
Drug: Both analgesics
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both analgesics
Study: 31722374
Drug: Anti-hyperglycemic medications
Normalized name: pramoxine hydrochloride Medicated Pad [Scalpicin Anti-Itch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-hyperglycemic medications
Study: 23141816
Drug: Serelaxin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serelaxin (30 μg/kg per day)
Study: 19217991
Drug: Fixed-dose warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose warfarin 1 mg per day
Study: 31479105
Drug: Dose-adjusted warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-adjusted warfarin
Study: 2178534
Drug: No warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: No warfarin
Study: 19217991
Drug: Warfarin (combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (combined fixed-dose and dose-adjusted)
Study: 11194244
Drug: Buffered regular
Normalized name: INSULIN,REGULAR,HUMAN BUFFERED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buffered regular human insulin
Study: 9385624
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg of immediate-release PPA (administered orally via a gelatin capsule)
Study: 7611920
Drug: Carvedilol (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (25 mg/day for 8 weeks)
Study: 7611920
Drug: Nifedipine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (40 mg/day b.i.d. for 8 weeks)
Study: 28318161
Drug: Periodontal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periodontal therapy and root-canal treatment (experimental group)
Study: 28318161
Drug: Periodontal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periodontal treatment alone (control group)
Study: 16450574
Drug: Desloratadine/pseudoephedrine, 2.5/120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desloratadine/pseudoephedrine, 2.5/120 mg b.i.d.
Study: 16450574
Drug: Desloratadine, 5
Normalized name: Desloratadine, 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desloratadine, 5 mg once per day
Study: 16450574
Drug: Pseudoephedrine, 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pseudoephedrine, 120 mg b.i.d.
Study: 12378662
Drug: Ropivacaine 2
Normalized name: fentanyl-ropivacaine 2 mcg/mL-0.1% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 2 mg ml‐1
Study: 12378662
Drug: Ropivacaine 5
Normalized name: fentanyl-ropivacaine 5 mcg/mL-0.1%-0.9% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 5 mg ml‐1
Study: 12378662
Drug: Ropivacaine 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 7.5 mg ml‐1
Study: 12378662
Drug: Ropivacaine 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 10 mg ml‐1
Study: 9924905
Drug: Vigabatrin (VGB)
DrugBank: Vigabatrin (DB01080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vigabatrin (VGB) 1 g/day
Study: 9924905
Drug: Vigabatrin (VGB)
DrugBank: Vigabatrin (DB01080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vigabatrin (VGB) 3 g/day
Study: 9924905
Drug: Vigabatrin (VGB)
DrugBank: Vigabatrin (DB01080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vigabatrin (VGB) 6 g/day
Study: 8849986
Drug: Isoflurane 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflurane 2% administered before sternotomy for ten minutes
Study: 8849986
Drug: Isoflurane 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflurane 2% administered after sternotomy for ten minutes
Study: 28608719
Drug: Home monitoring
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home monitoring intervention with spirometry and symptom monitoring twice per week.
Study: 24973731
Drug: Functionally orientated
Normalized name: Papaver orientale seed oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functionally orientated treatment (SDA)
Study: 23827658
Drug: Training, support,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Training, support, and activity therapy intervention
Study: 12921496
Drug: Methylprednisolone sodium
Normalized name: methylPREDNISolone sodium phosphate
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone sodium succinate 50 mg intravenous piggyback (IVPB) prior to infusion and repeated 1 hour into the infusion
Study: 12921496
Drug: Standard regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard regimen of acetaminophen 650 mg orally with diphenhydramine 50 mg intravenously
Study: 9477787
Drug: Root form
Approvals — FDA: no, EMA: no, PMDA: no
Description: Root form implants placed in augmented sinuses
Study: 3544625
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (KABI 2165) 5,000 U once daily
Study: 3544625
Drug: Conventional heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional heparin 5,000 IU twice daily
Study: 30961460
Drug: Omega-3 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 (2 g) plus Vitamin E (400 IU)
Study: 15923414
Drug: Home Treatment
Normalized name: Home-brew
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home Treatment (HT) with low molecular weight heparin (LMWH) followed by warfarin
Study: 15923414
Drug: Home Treatment
Normalized name: Home-brew
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home Treatment (HT) with low molecular weight heparin (LMWH) alone
Study: 15923414
Drug: Hospitalized treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hospitalized treatment with LMWH and warfarin
Study: 15923414
Drug: Hospitalized treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hospitalized treatment with LMWH alone
Study: 15923414
Drug: Hospitalized treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hospitalized treatment
Study: 1882906
Drug: sucralfate, 1
Normalized name: Sucralfate, 1 g oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: sucralfate, 1 g q.i.d., 0.5 hour before meals on an empty stomach or at bedtime
Study: 1882906
Drug: ranitidine, 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: ranitidine, 150 mg b.i.d.
Study: 1882906
Drug: sucralfate, 1
Normalized name: Sucralfate, 1 g oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: sucralfate, 1 g b.i.d. (before breakfast and at bedtime)
Study: 1882906
Drug: ranitidine, 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: ranitidine, 150 mg at bedtime
Study: 7057465
Drug: Supplemental albumin
Normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemental albumin therapy
Study: 7057465
Drug: Supplemental steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemental steroid therapy
Study: 24388622
Drug: ezetimibe +
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ezetimibe + fluvastatin (10 mg/day + 30 mg/day)
Study: 24388622
Drug: fluvastatin alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: fluvastatin alone (30 mg/day)
Study: 22107110
Drug: Text message
Approvals — FDA: no, EMA: no, PMDA: no
Description: Text message programme targeted at changing illness and medication beliefs over 18 weeks
Study: 21352639
Drug: Olopatadine hydrochloride
Normalized name: Olopatadine Hydrochloride
DrugBank: Olopatadine (DB00768)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olopatadine hydrochloride nasal spray 0.6% (OLO)
Study: 21352639
Drug: Azelastine hydrochloride
Normalized name: Azelastine Hydrochloride
DrugBank: Azelastine (DB00972)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Azelastine hydrochloride nasal spray 0.1% (AZE)
Study: 20805112
Drug: Colchicine (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine (1.0 mg twice daily for the first day followed by 0.5 mg twice daily for 1 month for patients ≥70 kg; halved doses for patients <70 kg or intolerant)
Study: 15195238
Drug: Trivalent inactivated
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent inactivated influenza virus vaccine (TVV) + Trivalent live cold‐adapted influenza virus vaccine (CAIV-T)
Study: 15195238
Drug: Trivalent inactivated
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent inactivated influenza virus vaccine (TVV) + Placebo (P)
Study: 7659479
Drug: HbOC (Haemophilus
Approvals — FDA: no, EMA: no, PMDA: no
Description: HbOC (Haemophilus b oligosaccharide conjugate vaccine) administered simultaneously with DTaP or DTP
Study: 7659475
Drug: DTaP vaccines
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTaP vaccines
Study: 7659479
Drug: DTP vaccines
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTP vaccines
Study: 23992556
Drug: Broccoli consumption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broccoli consumption (250 g/day for 10 days)
Study: 18372433
Drug: Iloprost 50
Normalized name: Iloprost
DrugBank: Iloprost (DB01088)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iloprost 50 microg twice daily
Study: 18372433
Drug: Iloprost 100
Normalized name: ILOPROST 100MCG/ML INJ,SOLN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iloprost 100 microg twice daily
Study: 18372433
Drug: Iloprost 150
Normalized name: Iloprost
DrugBank: Iloprost (DB01088)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iloprost 150 microg twice daily
Study: 9443519
Drug: Caffeinated coffee
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeinated coffee (1.5 mg/kg caffeine/body weight)
Study: 8197032
Drug: Ticarcillin-clavulanic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticarcillin-clavulanic acid (T-C) 3.1 g
Study: 8197032
Drug: Ampicillin-sulbactam (A-S)
Normalized name: ampicillin / sulbactam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin-sulbactam (A-S) 3 g
Study: 3295035
Drug: Captopril (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (25 or 50 mg given thrice daily)
Study: 3295035
Drug: Indomethacin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (50 mg given thrice daily)
Study: 17383080
Drug: BCG RIVM
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG RIVM 2 x 10(8) CFU weekly for 6 wk
Study: 17383080
Drug: MMC 20
Normalized name: MMC
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MMC 20 mg weekly for 6 wk
Study: 17383080
Drug: MMC 20
Normalized name: MMC
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MMC 20 mg weekly for 6 wk followed by monthly instillations for 3 yr
Study: 11207651
Drug: Albendazole treatment
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Albendazole treatment group
Study: 11444448
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (Control Group)
Study: 29362596
Drug: Cerebrolysin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerebrolysin (30 ml/day for 10 days)
Study: 26004611
Drug: EMG biofeedback
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMG biofeedback treatment after BTX-A injection
Study: 26004611
Drug: Botulinum toxin-A
Normalized name: Botulinum toxin A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Botulinum toxin-A (BTX-A) injection
Study: 21147712
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg iron as ferrous sulfate
Study: 22094835
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg iron as NaFeEDTA
Study: 19362994
Drug: Benfluorex (BFL)
Normalized name: benfluorex
DrugBank: Benfluorex (DB09022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benfluorex (BFL) 3 tablets/day for 24 weeks
Study: 16314385
Drug: Pro-active call
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pro-active call centre-based stepped treatment support
Study: 11401971
Drug: MACconj (meningococcal
Approvals — FDA: no, EMA: no, PMDA: no
Description: MACconj (meningococcal group A+C conjugate vaccine)
Study: 11401971
Drug: MACPS (meningococcal
Approvals — FDA: no, EMA: no, PMDA: no
Description: MACPS (meningococcal group A+C polysaccharide vaccine)
Study: 8988699
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate 10 mg
Study: 8988699
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate 20 mg
Study: 3307567
Drug: Chlorpheniramine maleate
Normalized name: Chlorpheniramine Maleate
DrugBank: Chlorpheniramine (DB01114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpheniramine maleate (CM) 4.0 mg orally, 4 times daily for 4 days
Study: 3307567
Drug: Diphenhydramine hydrochloride
Normalized name: Diphenhydramine Hydrochloride
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diphenhydramine hydrochloride (DH) 2 mg intranasally, 4 times daily for 5 days
Study: 9279176
Drug: Standard parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard parenteral nutrition
Study: 23649080
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg sublingual piroxicam (two 20‐mg tablets once daily on the first and second postoperative days, followed by one 20‐mg tablet on the third postoperative day)
Study: 23649080
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg oral diclofenac (50 mg thrice a day on the first, second, and third postoperative days)
Study: 12114372
Drug: BAYx1005 (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAYx1005 (500 mg bid)
Study: 10206217
Drug: Intravenously administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenously administered procainamide hydrochloride
Study: 7781621
Drug: Stricter guidelines
Normalized name: Euphrasia stricta extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stricter guidelines for diagnosis and treatment of gestational diabetes
Study: 31212248
Drug: Sertraline (∼1 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (∼1 μg L‐1)
Study: 31212248
Drug: Methamphetamine (∼1 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methamphetamine (∼1 μg L‐1)
Study: 27506203
Drug: Reinforcement-Induced Movement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reinforcement-Induced Movement Therapy (RIMT) with goal-oriented movement amplification in VR
Study: 24824360
Drug: Tryptophan intake
Normalized name: Tryptophan
DrugBank: Tryptophan (DB00150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tryptophan intake of 15 mg·kg·day
Study: 24824360
Drug: Recommended intake
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recommended intake of 29 mg·kg·day
Study: 20089937
Drug: Topiramate 25
Normalized name: topiramate 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate 25 mg/kg/d
Study: 20089937
Drug: Topiramate 15
Normalized name: topiramate 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate 15 mg/kg/d
Study: 20089937
Drug: Topiramate 5
Normalized name: topiramate 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate 5 mg/kg/d
Study: 18975532
Drug: Sevoflurane with
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevoflurane with nitrous oxide (Group G)
Study: 15983916
Drug: Etanercept (a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept (a soluble TNF receptor)
Study: 15983916
Drug: Anti-TNF antibody
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-TNF antibody infliximab
Study: 1481832
Drug: Folinic acid
Normalized name: Folinic acid
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Folinic acid (dl-Leucovorin, 15 mg/day)
Study: 31216086
Drug: Sofosbuvir-velpatasvir (400/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir-velpatasvir (400/100 mg) once daily for 12 weeks
Study: 19056576
Drug: Capsinoids (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsinoids (6 mg/d)
Study: 15559606
Drug: Both preparations
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both preparations of IFN‐beta 1‐a
Study: 9716578
Drug: Ticlopidine 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticlopidine 500 mg/d
Study: 9716578
Drug: Aspirin 325
Normalized name: aspirin 325 MG
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 325 mg/d + Ticlopidine 500 mg/d
Study: 8383688
Drug: Granisetron 40
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Granisetron 40 micrograms/kg (additional doses allowed)
Study: 7021163
Drug: Bronchodilator aerosol
Normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bronchodilator aerosol with tube extension (terbutaline sulphate 0.25 mg)
Study: 31029045
Drug: Higher cocoa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher cocoa chocolate (HCC; ∼90%; 20 g daily)
Study: 31029045
Drug: Lower cocoa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower cocoa chocolate (LCC; ∼55%; 20 g daily)
Study: 23996803
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg nebivolol per day for 3 months
Study: 14734063
Drug: 5-fluorouracil (25mg/ml)
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluorouracil (25mg/ml) treatment for 5 minutes
Study: 31318748
Drug: Extracorporeal shock
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal shock wave therapy (n = 32)
Study: 28061321
Drug: Subcutaneous vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous vitamin E ointment application (Group 1)
Study: 28061321
Drug: No vitamin
Normalized name: Vitamin B12 NOS
DrugBank: Cyanocobalamin (DB00115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No vitamin E ointment application (Group 2)
Study: 26001670
Drug: Integrative cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrative cognitive behavioral therapy for PGD (PG-CBT)
Study: 21129746
Drug: Non-users of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-users of lipid-lowering treatment (LLT)
Study: 19413147
Drug: PLMS indexes
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLMS indexes of children who were medication free for a third and fourth night (n = 7) or just a third night (n = 2)
Study: 17388751
Drug: Inhalation technique
Normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation technique
Study: 17388751
Drug: Inhalation resistance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation resistance
Study: 15220017
Drug: Diazepam (0.28
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (0.28 mg/kg IV)
Study: 11231977
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogen, 0.625 mg/day
Study: 9748117
Drug: 5FU dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5FU dose adjusted according to the 5FU area under the curve (AUC0‐48h; PK‐arm)
Study: 9748117
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose of 5FU (St‐arm; 4 g/m2)
Study: 8040918
Drug: Alcohol Skills
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol Skills Training Program (ASTP), a cognitive behavioral approach, details of dosage and duration not specified.
Study: 18356686
Drug: Aspirin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (100 mg) + Propranolol (80 mg)
Study: 16609087
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (various regimens including cyclophosphamide, doxorubicin, fluorouracil, and paclitaxel) for ER-negative tumors
Study: 16609087
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (various regimens including cyclophosphamide, doxorubicin, fluorouracil, and paclitaxel) for ER-positive tumors
Study: 16609087
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy for ER-negative tumors
Study: 16609087
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy for ER-positive tumors